Search
Tenofovir alafenamide
go.drugbank.com/drugs/DB09299ApprovedInvestigational[A178060] Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal … [A178219] It has been reported to produce a large antiviral efficacy at doses ten times lower than tenofovir disoproxil.
Categories: Antivirals used in combination for the treatment of HIV infectionsAcute Pain
go.drugbank.com/conditions/DBCOND0003831Methyltestosterone
go.drugbank.com/drugs/DB06710ApprovedInvestigationalA synthetic anabolic steroid used for treating men with testosterone deficiency or similar androgen replacement therapies. … Methyltestosterone is a schedule III drug in the US.
Categories: Sex Hormones and Modulators of the Genital SystemSynonyms: 17α-methyl-Δ4-androsten-17β-ol-3-one, 17alpha-Methyl-3-oxo-4-androsten-17beta-olColfosceril palmitate
go.drugbank.com/drugs/DB09114ApprovedWithdrawnColfosceril palmitate is a synthetic pulmonary surfactant administered in infants with respiratory distress syndrome. … [A31510] It was part of the first generation of commercially available artificial surfactants.[T70] It was developed by Burroughs Wellcome and it was FDA approved on August 6, 1990.
Synonyms: Palmitate de colfosceril, Palmitato de colfosceriloIdelalisib
go.drugbank.com/drugs/DB09054ApprovedInvestigationalFor the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other … The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexPolymyxin B
go.drugbank.com/drugs/DB00781ApprovedInvestigationalVet approvedPolymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429]. … It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label].
Mixtures: IQFAIN-OF, OP Triple AntibioticProducts: POLİX 500000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ (POLİMİSİN), 10 FLAKON, POLİX 500000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN LİYOFİLİZE TOZ (POLİMİSİN), 1 FLAKONFencamfamin
go.drugbank.com/drugs/DB01463ApprovedIllicitWithdrawnIt is around half the potency of [dexamphetamine], and is prescribed at a dose of 10-60mg, although abusers of the drug tend to rapidly develop tolerance and escalate their dose. … Fencamfamin is used for treating depressive day-time fatigue, lack of concentration and lethargy. It is especially useful in patients with chronic conditions due to its favourable safety profile.
Yohimbine
go.drugbank.com/drugs/DB01392ApprovedInvestigationalVet approvedWithdrawnA plant alkaloid with alpha-2-adrenergic blocking activity. Yohimbine has been used as a mydriatic and in the treatment of impotence. It is also alleged to be an aphrodisiac.
Categories: Dopamine D2 Receptor Antagonists, Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeVosoritide
go.drugbank.com/drugs/DB11928ApprovedInvestigational[A242273] While the remarkably short half-life of endogenous CNP - 2 to 3 minutes due to its rapid degradation by endopeptidases - makes it ineffective as a therapeutic intervention,[A242273] the development … of a condition like achondroplasia.
Categories: Drugs for Treatment of Bone DiseasesTagraxofusp
go.drugbank.com/drugs/DB14731ApprovedInvestigationalIt is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_. … [A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is